Document is current

Article History

Accepted: 8 January 2025

First Online: 10 March 2025

Declarations

:

: ZM reports paid work for UCL Business Company Spoonful of Sugar. JF reports grants GlaxoSmithKline. FB reports grants and personal fees from Gilead Sciences. AU reports personal fees from Generate, Gilead Sciences, ViiV Healthcare/GlaxoSmithKline, Merck/MSD, Moderna and Pfizer. AC reports grants and personal fees from Gilead Sciences, grants and personal fees from ViiV Healthcare/GlaxoSmithKline, and grants and personal fees from MSD. SS reports personal fees from ViiV Healthcare and grants from Gilead Sciences, ViiV Healthcare/GlaxoSmithKline, and MSD. FAP reports personal fees from Gilead Sciences, ViiV Healthcare/GlaxoSmithKline and MSD, and grants from Gilead Sciences, ViiV Healthcare/GlaxoSmithKline and MSD. RH reports grants/research support from AstraZeneca; National Institute for Health Research (NIHR), Collaboration for Leadership in Applied Health Research and Care (CLAHRC), North Thames at Bart’s Health NHS Trust and Asthma UK (AUKCAR); Honoraria/consultation fees: AbbVie, Amgen, Astellas, AstraZeneca, Biogen, Erasmus, Idec, Gilead Sciences, GlaxoSmithKline, Janssen, Merck Sharp Dohme, Novartis, Pfizer, Roche, Shire Pharmaceuticals, TEVA. Founder and shareholder of a UCLBusiness company (Spoonful of Sugar Ltd) providing consultancy on supporting patients with medicines and treatment related behaviours to healthcare policy makers, providers and industry. All other authors declare no conflicts of interest.

: All procedures performed in studies involving human participants were in accordance with the ethical standards of the institutional and/or national research committee and with the 1964 Helsinki Declaration and its later amendments or comparable ethical standards. The study was approved by a National Health Service Research Ethics Committee (21/ES/0047) and the Health Research Authority (IRAS 294887).

: Informed Consent was obtained from all individual participants included in the study.